Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04608318 |
| Title | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17) |
| Acronym | CLL17 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | German CLL Study Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | SWE | NOR | NLD | ITA | ISR | IRL | FIN | ESP | DNK | DEU | CHE | BEL | AUT |